If this was the case and companies waited until there was almost no risk then nothing would ever get bought out after ph1 or ph2 and ph2 is the sweet spot for a large % of buyouts given what oh2 trials cost to run. We aren’t talking buyouts though, we are just talking a small amount of money to big pharma companies to put in to fund trials to possibly make a hell of a lot more than their outlay. Agree that at least we will get an answer in roughly a year though so there’s some sort of finish line (or start line) depending on how the results fare.
PAR Price at posting:
42.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)